van der Pol M, Watson V, Boyers D. Stability of willingness to pay: does time and treatment allocation in a randomized controlled trial influence willingness to pay? Med Decis Making. 2024 Jul;44(5):470-80. doi: 10.1177/0272989X241249654.
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Vickers A. An evaluation of survival curve extrapolation techniques using long-term observational cancer data. Med Decis Making. 2019 Nov;39(8):926-38. doi: 10.1177/0272989X19875950
Watson V, Porteous T, Bolt T, Ryan M. Mode and frame matter: assessing the impact of survey mode and sample frame in choice experiments. Med Decis Making. 2019 Oct;39(7):827-41. doi: 10.1177/0272989X19871035
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, Macgillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Cruden G, Spencer J, Dong OM. Improving the identification of adolescent depression through primary care screening approaches. Presented at the 40th Annual Meeting of the Society for Medical Decision Making; October 17, 2018. Montreal, Canada. [abstract] Med Decis Making. 2018 Dec 27; 39(1):E272. doi: 10.1177/0272989X18821191
Vass C, Rigby D, Tate K, Stewart A, Payne K. An exploratory application of eye-tracking methods in a discrete choice experiment. Med Decis Making. 2018 Aug;38(6):658-72. doi: 10.1177/0272989X18782197
Rowen D, Labeit A, Stevens K, Elliott J, Mulhern B, Carlton J, Basarir H, Brazier J. Estimating a preference-based single index measuring the quality-of-life impact of self-management for diabetes. Med Decis Making. 2018 Aug;38(6):699-707. doi: 10.1177/0272989X18784291
Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Brookhart MA. Injection testosterone and adverse cardiovascular events: a case-crossover analysis. Clin Endocrinol (Oxf). 2018 May;88(5):719-27. doi: 10.1111/cen.13574
Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT. Two-stage biomarker protocols for early detection of prostate cancer. Med Decis Making. 2017 Oct;37(7):815-26. doi: 10.1177/0272989X17696996
Vass C, Rigby D, Payne K. The role of qualitative research methods in discrete choice experiments. Med Decis Making. 2017 Apr;37(3):298-313. doi: 10.1177/0272989X16683934
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Making. 2016 Nov;36(8):1020-33. doi: 10.1177/0272989X16658660.
Kruger J, Pollard D, Basarir H, Thokala P, Cooke D, Clark M, Bond R, Heller S, Brennan A. Incorporating psychological predictors of treatment response into health economic simulation models: a case study in type 1 diabetes. Med Decis Making. 2015 Oct;35(7):872-87. doi: 10.1177/0272989X15590143
Davis AE, Mehrotra S, Friedewald JJ, Daskin MS, Skaro AI, Abecassis MM, Ladner DP. Improving geographic equity in kidney transplantation using alternative kidney sharing and optimization modeling. Med Decis Making. 2015 Aug;35(6):797-807. doi: 10.1177/0272989X14557696
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Alvarez-Pedrerol M, Ribas-Fito N, Garcia-Esteban R, Rodriguez A, Soriano D, Guxens M, Mendez M, Sunyer J. Iodine sources and iodine levels in pregnant women from an area without known iodine deficiency. Clin Endocrinol (Oxf). 2010 Jan;72(1):81-6. doi: 10.1111/j.1365-2265.2009.03588.x
Eberth B, Watson V, Ryan M, Hughes J, Barnett G. Does one size fit all? Investigating heterogeneity in men's preferences for benign prostatic hyperplasia treatment using mixed logit analysis. Med Decis Making. 2009 Nov;29(6):707-15. doi: 10.1177/0272989X09341754
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Earnshaw SR, Richter A, Sorensen SW, Hoerger TJ, Hicks KA, Engelgau M, Thompson T, Narayan KMV, Williamson DE, Gregg E, Zhang P. Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making. 2002 Jan 1;22(5):S80-91.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Wirén L, Whalley D, McKenna SP, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrinol (Oxf). 2000 Feb;52(2):143-52.
McKenna S, Doward LC. Measuring quality of life in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 Oct;45(4):507-8.